Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

Triple Negative Breast Cancer (TNBC) is a challenging disease due to the lack of druggable targets; therefore, chemotherapy remains the standard of care and the identification of new targets is a high clinical priority. Alterations in the components of the cell cycle machinery have been frequently r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cretella, Daniele, Fumarola, Claudia, Bonelli, Mara, Alfieri, Roberta, La Monica, Silvia, Digiacomo, Graziana, Cavazzoni, Andrea, Galetti, Maricla, Generali, Daniele, Petronini, Pier Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736958/
https://www.ncbi.nlm.nih.gov/pubmed/31506466
http://dx.doi.org/10.1038/s41598-019-49484-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736958/
https://www.ncbi.nlm.nih.gov/pubmed/31506466
http://dx.doi.org/10.1038/s41598-019-49484-4

Ejemplares similares